N/A N=35 Genetic Response to Warfarin in Healthy Subjects
Healthy
Primary: Median Cumulative Therapeutic Warfarin Dose (Milligrams)Requirements by Genotype — 52; 52; 17; 35 milligrams
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=3,182 BLOOM: Behavioral Modification and Lorcaserin for Overweight and Obesity Management
Obesity
Primary: Year 1: Co-Primary Endpoint- Proportion (%) of Patients Achieving > or = 5% Weight Loss From Baseline to Week 52 — 47.5; 20.3 percentage of participants — p=<0.0001
Phase 3 N=4,008 BLOSSOM: Behavioral Modification and Lorcaserin Second Study for Obesity Management
Obesity
Primary: Co-primary Endpoint- Percentage of Participants Achieving Greater Than or Equal to 5% Weight Loss From Baseline to Week 52 — 40.2; 47.2; 25.0 percentage of participants…
Phase 2 N=35 RAD001 in Patients With Metastatic, Hormone-Refractory Prostate Cancer
Hormone Refractory Prostate Cancer
Primary: Biochemical Response Rate — 0 participants
Phase 3 N=12 Lapatinib in Combination With Weekly Paclitaxel in Patients With ErbB2 Amplified Advanced Gastric Cancer
Neoplasms, Gastrointestinal Tract
Primary: Number of Participants With Dose Limiting Toxicities (DLTs) in the Pilot Part of the Study — 2; 1 Participants
Phase 2 N=34 Telemedicine To Provide Inflammatory Bowel Disease Outpatient Care
Inflammatory Bowel Disease · Ulcerative Colitis · Crohn's Disease
Primary: Patient Clinical Experience — 1.2; 1.3 units on a scale — p=<0.05
Phase 2 N=236 Self Hypnotic Relaxation As An Adjunct To Local Anesthesia During Large Core Breast Biopsy
Breast Cancer · Anxiety · Pain
Primary: Anxiety Ratings at Specified Time Point During the Procedure — 4.5; 5; 5 units on a scale
Phase 2 N=30 An add-on Study of E2007 in Patients With Refractory Partial Seizures Uncontrolled With Other Anti-epileptic Drugs (AEDs)
Refractory Partial Seizures
Primary: Maximum Tolerated Dose (MTD) — 0; 2; 1; 6 Participants
N/A N=789 EValuation of HumIRA® in Patients With Active Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis in EASTern European Countries
Ankylosing Spondylitis (AS) · Psoriatic Arthritis (PsA · Rheumatoid Arthritis (RA
Primary: Clinical Outcome (Disease Activity Score [DAS28] Decrease ≥1.2) After 3 Months of Humira Therapy Relative to Baseline in Participants With RA — 56; 251; 78 participants
Phase 4 N=60 TissueLink Study During Multi-Level Spine Surgery
Low Back Pain
Primary: Hemoglobin Measurement g/dl — 66.2; 102.4 hemoglobin g/dl
Phase 2 N=198 Cavitation Ultrasound in Treatment of Patients With PCOS
PCOS
Primary: Clinical Pregnancy Rate — 12; 5; 16 participants
Phase 4 N=216 PROUD Study: A Prospective Study on the Usage Patterns of Doripenem in the Asia Pacific Region
Pneumonia · Pneumonia, Ventilator-Associated · Urinary Tract Infections
Primary: Number of Participants With the Usage of Doripenem as Per the Approved Indication — 23; 0; 0; 0 Participants
Phase 3 N=118 Efficacy, Pharmacokinetics, Safety, and Immunogenicity Study of Abatacept Administered Subcutaneously to Treat Rheumatoid Arthritis in Japanese Patients
Rheumatoid Arthritis
Primary: Percentage of Participants With an American College of Rheumatology (ACR) 20 Response at Day 169 in Short Term Period — 91.5; 83.1 Percentage of participants
Phase 4 N=131 Effect of Orlistat in Body Composition
Obesity · Overweight
Primary: Change From Baseline to Week 24 in Abdominal VAT Mass — -0.630; -0.403 kg — p=0.0244
Phase 4 N=41 How Glargine Insulin, Oral Diabetes Medications and Exenatide May Improve Blood Sugar Control and Weight Gain in Type 2 Diabetics
Type 2 Diabetes
Primary: The Percentage of Intent to Treat Participants Randomized and Treated in Each Arm Who Had Lab-measured A1c <6.5% at 24 Weeks of Treatment — 47; 12 percentage of…